QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

• Status: Terminated
• Trial end date: 2010-08-01

Summary

This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Amgen; NantCell, Inc.
• Treatments: Albumin-Bound Paclitaxel; Antibodies; Antibodies, Monoclonal; Carboplatin; Paclitaxel